A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorMirador Therapeutics, Inc.
About this trial
This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.
Eligibility criteria
Qualifiers
Diagnosis of Crohn's Disease (CD), as confirmed by endoscopy and histopathology
Moderately to severely active CD as defined by Clinical Disease Activity Index (CDAI) and Simple Endoscopic Score (SES-CD)
Meets drug stabilization requirements
Diagnosis of Ulcerative Colitis (UC), as confirmed by endoscopy and histopathology
Disqualifiers
Diagnosis of indeterminate colitis
Suspected or diagnosed intra-abdominal or perianal abscess at Screening
Previous small bowel resection with combined resected length of > 100 cm or previous colonic resection of > 2 segments
CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic and/or ileal involvement
Trial design
Treatments tested in this trial
- MT-501
- MT-201
Treatment groups
140 Participants
are divided into 3 treatment groupsLocations
66Canada
Mirador Therapeutics Selected Site Toronto Canada
Georgia
Mirador Therapeutics Selected Site Kutaisi Georgia
Mirador Therapeutics Selected Site Marneuli Georgia
Mirador Therapeutics Selected Site0102, Tbilisi Georgia
Sponsors and collaborators
Mirador Therapeutics, Inc.
Lead sponsor
Source ClinicalTrials.gov